The international, phase III, multicenter AZA-001 trial demonstrated AZA is the first treatment to significantly extend overall survival (OS) in higher-risk MDS pts (Fenaux, Blood2007;110:817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and...
背景:III期随机QUAZAR AML-001研究(NCT01757535)证实,与安慰剂相比,口服阿扎胞苷(AZA)可显著改善强化化疗(IC)后首次疾病缓解的老年急性髓系白血病(AML)患者的OS和无复发生存期(RFS),且口服AZA带来的OS和RFS获益不受到患者IC后MRD状态的影响。研究人员对QUAZAR AML-001研究数据进行了事后分析,旨在进一步探索口服AZA对...
Notably, the treatment with AZA significantly increased overall survival in patients with high-risk MDS as compared with conventional treatments (clinical trial: AZA-001)10. However, the mechanism of action of DNMT inhibitors has not been clearly defined11–16. We previously investigated the effects...
These data confirm the pivotal QUAZAR AML -001 trial results showing OS benefit of Oral-AZA versus no active maintenance therapy, further supporting consistent drug use in all eligible patients in clinical practice. 展开 关键词: AML maintenance oral azacitidine ...
A randomized double-blind, double-dummy, multicenter trial of azasetron versus ondansetron to evaluate efficacy and safety in the prevention of delayed nausea and vomiting induced by chemotherapy. Cancer Res Treat. 2014; 46:19–26. https://doi.org/10.4143/crt.2014.46.1.19. 16. Rosenblatt E, ...
He noted that this study, QUAZAR AML-001 (NCT01757535), was not powered to detect significant differences between consolidation subgroups. “Furthermore, a broad assessment of the impact of consolidation therapy in for the front-line management of AML was not the focus of this trial. An...
This trial reported a 34% overall response rate with 5-AZA-CdR and an improvement in the progression-free survival (0.55 versus 0.25 years; P = 0.004) compared with the findings for the BSC group. The time to AML progression and overall survival, however, did not differ significantly ...
This trial reported a 34% overall response rate with 5-AZA-CdR and an improvement in the progression-free survival (0.55 versus 0.25 years; P = 0.004) compared with the findings for the BSC group. The time to AML progression and overall survival, however, did not differ significantly ...
About 33% of patients (pts) in AZA-AML-001 had AML with morphologic dysplastic changes (AML-MDC).Aim: Determine effects of AZA vs CCR on OS, response, and safety in the subset of pts with AML-MDC in the AZA-AML-001 trial; and further analyze OS in AML-MDC pts who had been ...
Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 TrialWei, Andrew H.Dhner, Hartmut